# TEC

Source: https://onco.cc/targets/tec/  
OnCo record `tec` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.

## Summary

Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells.

IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Oesophageal Squamous Cell Carcinoma. In OnCo, 2 product records name it (Ibrutinib and Acalabrutinib).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: tec protein tyrosine kinase; Tyrosine-protein kinase Tec; PSCTK4
- Tags: cancer-genes-wave
- Symbol: TEC
- Class: kinase
- Biology: Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. Required for TCR-dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific substrate, and contributes to CD28-signalling. Mediates signals that negatively regulate IL2RA expression induced by TCR cross-linking. Location: Cytoplasm; Cell membrane; Cytoplasm, cytoskeleton (UniProt). Locus 4p12-p11 (HGNC).
- Where found: Oesophageal cancer: IntOGen driver in 1 cohort (ESCC); Oesophageal squamous cell carcinoma: IntOGen driver in 1 cohort (ESCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: 2 OnCo product records name it; IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11719: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11719
- UniProt P42680: https://www.uniprot.org/uniprotkb/P42680/entry
- NCBI Gene 7006: https://www.ncbi.nlm.nih.gov/gene/7006
- Ensembl ENSG00000135605: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135605

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/)

---
JSON: https://onco.cc/api/v1/entities/tec.json